Christopher Tompkins, PhD, joined KromaTiD in 2011. He is the president and general manager and is a member of the board of directors. He has 20 years of pharmaceutical and biotechnology industry experience focused in the areas of process development, operations, and the commercialization of new technologies.
Christopher's past experience includes being COO at Evia Medical, vice president of Operations and chief compliance officer at Atrius Bioscience, general manager of Proligo LLC, and other executive roles at Proligo. He has also led projects and performed engineering development for two marketed pharmaceutical products: at NeXstar Pharmaceuticals, he led the development team and designed the reactor technology for the macular degeneration treatment Macugen™; and at Hoffmann-La Roche he was jointly responsible for the development and scale-up of the 5-FU pro-drug Xeloda™.
Christopher graduated with a Bachelor of Science degree in Chemical Engineering from the University of Michigan and a PhD in Chemical Engineering from North Carolina State University.